Amedisys Reports Fourth Quarter and Year End 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Amedisys (AMED) Misses Q4 EPS by 10c, Beats on Revenue
February 26, 2025 4:32 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $0.96, $0.10 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $598.1 million versus the consensus estimate of $596.76 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
... More